Anticancer Research 1990-01-01

Daunorubicin coupled to monoclonal antibodies via a cis-aconitic anhydride linker: biochemical and cytotoxic properties revisited.

A Ahmad, K L Law, B Young, M W Telander, J R Ogden, K Leung

Index: Anticancer Res. 10(3) , 837-43, (1990)

Full Text: HTML

Abstract

Daunorubicin (DNR) was coupled to monoclonal antibodies (Mab) reactive to breast tumor cells using the acid-labile linking agents cis-asonitic anhydride and two other non acid-labile analogs, glutaric anhydride and citraconic anhydride. The acid derivatives of DNR formed by reaction with the anhydrides were converted to their N-hydroxysuccinimide (NHS) active esters for coupling to MAb. The molar input of drug NHS ester to MAb ranged from 1:1 to 100:1. The resulting MAb-DNR conjugates were purified by gel filtration and analyzed by high performance liquid chromatography. Monomeric conjugates contained 0.2 to 11.0 moles of DNR/mole of MAb. No evidence of cell killing was observed up to a concentration of 10 micrograms/ml DNR bound to MAb, while DNR exhibited 50% killing of the breast tumor cell line MCF-7 at a concentration of 1 microgram/ml.


Related Compounds

Related Articles:

Enhanced shRNA delivery and ABCG2 silencing by charge-reversible layered nanocarriers.

2015-02-25

[Small 11(8) , 952-62, (2015)]

Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release.

2015-05-01

[Drug Deliv. 22 , 389-99, (2015)]

Acid-responsive PEGylated doxorubicin prodrug nanoparticles for neuropilin-1 receptor-mediated targeted drug delivery.

2015-12-01

[Colloids Surf. B Biointerfaces 136 , 365-74, (2015)]

Cerebellar Purkinje cells incorporate immunoglobulins and immunotoxins in vitro: implications for human neurological disease and immunotherapeutics.

2009-01-01

[J. Neuroinflammation 6 , 31, (2009)]

Lectin-mediated drug targeting: preparation, binding characteristics, and antiproliferative activity of wheat germ agglutinin conjugated doxorubicin on Caco-2 cells.

1998-07-01

[Pharm. Res. 15(7) , 1031-7, (1998)]

More Articles...